Index tracked: MSCI Japan Select Screened Index (JPY)
TER
0.25%+ trans. 0.01%
Fund size
452 m EUR
Tracking difference
—not computable
🇮🇹 tax rate
—white list not published
Replication
Physical
Income
Accumulating
Launch 31 Mar 2015 · costs from the KID as of 2 Sept 2026 · 155 securities held · 9 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The fund is passively managed.
INVESTMENT OBJECTIVE:
The aim is for your investment to track the performance of the MSCI Japan Select Screened Index (index), while seeking to minimise foreign currency fluctuations at share class level.
DESCRIPTION OF INDEX:
The index is based on the MSCI Japan Index (Parent Index), which is designed to reflect the performance of the shares of large and medium capitalisation companies in Japan. In order to be eligible for inclusion in the index, companies must be eligible for inclusion in the Parent Index and must…
Performance since series start (in euro) — base 100
6 Feb 2015 → 8 Sept 2026 · dividends reinvested where declared by the issuer
High 292 (12 Aug 2026) · low 72 (8 Jul 2016) · last 286. Past performance is not indicative of future results.
RebalixIE00BRB36B93 · IE00BRB36B93 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years
Not honestly computable: hedged class: the issuer’s published index is unhedged — the gap would measure the exchange rate, not replication. We don’t show it
Holdings
Portfolio as declared by the issuer · 2 Sept 2026 · 155 securities · top-10 weight = 31.7%
The live sheet, always up to date rebalix.com/en/etf/IE00BRB36B93 Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.